UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 227, 2026

VOYAGER ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

Cayman Islands		001-42211		00-0000000N/A
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

131 Concord Street

Brooklyn, NY 11201

(Address of principal executive offices)

(347) 720-2907

(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

☒	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one Class A ordinary share and one half of one redeemable warrant	VACHU	The Nasdaq Stock Market LLC
Class A ordinary shares, par value $0.0001 per share	VACH	The Nasdaq Stock Market LLC
Warrants, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, exercisable 30 days after the completion of our initial business combination and will expire five years after the completion of our initial business combination or earlier upon redemption or our liquidation	VACHW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 17.01 ~~Entry~~Regulation ~~Into~~FD ~~A Material Definitive Agreement~~Disclosure.

~~Amendment~~On March 2, 2026, VERAXA Biotech AG, a company duly organized, validly existing, and in good standing under the laws of Switzerland (“VERAXA” or “Company”) will issue a press release (the “Press Release”) announcing that the VERAXA shareholders approved the merger and issuance of new shares to ~~Business~~Voyager ~~Combination~~Acquisition ~~Agreement~~Corp., a Cayman Islands exempted company (“SPAC”). The Press Release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of SPAC under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibit 99.1.

OnForward-Looking February 2, 2026, Voyager Acquisition Corp. (the “Company”) entered into that certain Second Amendment and Waiver (the “Amendment”) to that certain Business Combination Agreement dated as of April 22, 2025 as amended on October 18, 2025 (the “BCA”), by and among the Company, Veraxa Biotech AG (“Veraxa”), and Oliver Baumann, in his capacity as representative for the shareholders of Veraxa.Statements

~~Pursuant~~This toCurrent ~~the~~Report ~~Amendment~~on Form 8-K, including the ~~parties~~description toof the ~~BCA~~transactions, ~~agreed~~agreements, toand ~~increase~~other information contained herein and the ~~aggregate~~exhibits ~~merger~~hereto ~~consideration~~(collectively, this “Communication”) includes “forward-looking statements” within the meaning of the federal securities laws with respect to $1the Business Combination,~~350~~ and also contains certain financial forecasts and projections. All statements other than statements of historical fact contained in this Communication,~~000~~ including,~~000~~ but not limited to, statements ~~from~~as $1to future results of operations and financial position,~~300~~ planned products and services,~~000~~ business strategy and plans,~~000.~~ Inobjectives of ~~addition~~management for future operations of the Company, ~~Veraxa~~market ~~agreed~~size toand ~~waive~~growth ~~Section~~opportunities, ~~7.3(a)(i)~~competitive ~~solely~~position, totechnological ~~allow~~and market trends and the ~~Company~~potential tobenefits ~~propose~~and expectations related to the ~~amendment~~terms and timing of ~~its~~the ~~amended~~proposed ~~and~~Business ~~restated~~Combination, ~~memorandum~~are ~~and~~forward-looking statements. ~~articles~~Some of ~~association~~these atforward-looking astatements ~~meeting~~can be identified by the use of ~~its~~forward-looking ~~shareholders~~words, inincluding ~~order~~“anticipate,” “expect,” to“suggests,” ~~remove~~“plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” or other similar expressions. All forward-looking statements are based upon estimates and forecasts and reflect the ~~net~~views, ~~tangible~~assumptions, ~~asset~~expectations, ~~requirement~~and ~~therein~~opinions of $5SPAC and the Company,~~000~~ which are all subject to change due to various factors. Any such estimates,~~001~~ assumptions, expectations, forecasts, views or opinions, whether or not identified in this Communication, should be regarded as indicative, preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results.

~~Sponsor~~The ~~Support~~forward-looking statements ~~Agreement~~and financial forecasts and projections contained in this Communication are subject to a number of factors, risks and uncertainties. Potential risks and uncertainties that could cause the actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to, changes in domestic and foreign business, market, financial, political and legal conditions; the timing and structure of the Business Combination; changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations; the inability of the parties to successfully or timely consummate the Business Combination and the other transactions in connection therewith, including as a result of any regulatory approvals that are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the Business Combination or that the approval of the shareholders of SPAC or the Company is not obtained; the risk that the business combination disrupts current plans and operations of SPAC or the Company as a result of the announcement and consummation of the Business Combination; the ability of the Company to grow and manage growth profitably and retain its key employees including its chief executive officer and executive team; the inability to obtain or maintain the listing of Veraxa Biotech Holding AG’s (“PubCo”) securities on the Nasdaq Stock Market LLC following the Business Combination; failure to realize the anticipated benefits of the Business Combination; risk relating to the uncertainty of the projected financial information with respect to the Company; the amount of redemption requests made by SPAC’s shareholders and the amount of funds available in the SPAC’s trust account; the overall level of demand for the Company’s services; general economic conditions and other factors affecting the Company’s business; the Company’s ability to implement its business strategy; the Company’s ability to manage expenses; changes in applicable laws and governmental regulation and the impact of such changes on the Company’s business, the Company’s exposure to litigation claims and other loss contingencies; the risks associated with negative press or reputational harm; the Company’s ability to protect patents, trademarks and other intellectual property rights; any breaches of, or interruptions in, the Company’s technology infrastructure; changes in tax laws and liabilities; and changes in legal, regulatory, political and economic risks and the impact of such changes on the Company’s business. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of PubCo’s Registration Statement (as defined below), the proxy statement/consent solicitation statement/prospectus discussed below and other documents filed by PubCo or SPAC from time to time with the U.S. Securities and Exchange Commission (the “SEC”). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. In addition, there may be additional risks that neither SPAC nor the Company presently know, or that SPAC or the Company currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Forward-looking statements reflect SPAC’s and the Company’s expectations, plans, projections or forecasts of future events and view. If any of the risks materialize or SPAC’s or the Company’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.

On February 2, 2026, Veraxa and Voyager Acquisition Sponsor Holdco LLC (the “Sponsor”) entered into that certain First Amendment to Sponsor Support Agreement, amending that certain Sponsor Support Agreement dated as of April 22, 2025 (the “Sponsor Support Agreement”), between the Company, Veraxa and the Sponsor, pursuant to which the Sponsor agreed, in connection with the Closing (as defined in the BCA), to forfeit for cancellation for no consideration 200,000 Class B Ordinary Shares (as defined in the BCA) and 400,000 SPAC Warrants (as defined in the BCA) for which a corresponding number of PubCo Ordinary Shares (as defined therein) and PubCo Warrants (as defined in the BCA) will be issued to shareholders of Veraxa.1

~~All~~Forward-looking ~~terms~~statements speak ~~used~~only inas ~~this~~of ~~Item 1~~the date they are made.01 SPAC and ~~not~~the ~~defined~~Company ~~herein~~anticipate ~~shall~~that ~~have~~subsequent events and developments may cause their assessments to change. However, while PubCo, SPAC and the ~~meanings~~Company ~~set~~may ~~forth~~elect to update these forward-looking statements at some point in the ~~BCA~~future, PubCo, SPAC and ~~Sponsor~~the ~~Support~~Company ~~Agreement~~specifically disclaim any obligation to do so, except as required by law. The ~~foregoing~~inclusion ~~summaries~~ of any statement in this document does not constitute an admission by the ~~Amendment~~Company ~~and~~nor SPAC or any other person that the ~~Sponsor~~events ~~Support~~or ~~Agreement~~circumstances dodescribed in ~~not~~such ~~purport~~statement toare material. These forward-looking statements should not be ~~complete~~relied ~~and~~upon ~~are~~as ~~qualified~~representing inSPAC’s ~~their~~or ~~entirety~~the byCompany’s assessments ~~reference~~as of any date subsequent to the ~~Amendment~~date ~~and~~of this document. Accordingly, undue reliance should not be placed upon the ~~Sponsor~~forward-looking statements. ~~Support~~In ~~Agreement~~addition, ~~copies~~the analyses of ~~which~~the ~~are~~Company ~~filed~~and asSPAC ~~Exhibit~~contained ~~2.1~~herein are not, and ~~Exhibit~~do ~~10.1~~not ~~and~~purport ~~are~~to ~~incorporated~~be, byappraisals ~~reference~~of ~~herein~~the securities, assets or business of the Company, SPAC or any other entity.

~~Forward-Looking~~Important ~~Statements~~Information About the Proposed Transactions and Where to Find It

This ~~Current Report on Form 8-K, including the description of the transactions, agreements, and other information contained herein and the exhibits hereto (collectively, this “~~Communication”) ~~includes “forward-looking statements” within the meaning of the federal securities laws with respect~~ relates to ~~the~~a proposed Business Combination, ~~and~~between ~~also~~the ~~contains~~Company ~~certain financial forecasts~~ and ~~projections~~SPAC. ~~All~~This ~~statements~~document ~~other~~does ~~than~~not ~~statements~~constitute ofan ~~historical~~offer ~~fact~~to ~~contained~~sell inor ~~this Communication~~exchange, ~~including,~~or ~~but~~the solicitation ~~not~~of ~~limited~~an ~~to,~~offer ~~statements as~~ to ~~future~~buy ~~results~~or ~~of operations and financial position~~exchange, ~~planned~~any ~~products and services~~securities, ~~business~~nor ~~strategy~~shall ~~and~~there ~~plans,~~be ~~objectives~~any ofsale ~~management for future operations~~ of ~~the~~securities ~~Company~~in ~~and~~any ~~Veraxa,~~jurisdiction ~~market~~in ~~size~~which ~~and growth opportunities~~such offer, ~~competitive~~sale ~~position,~~or ~~technological~~exchange ~~and~~would ~~market~~be ~~trends~~unlawful ~~and~~prior ~~the~~to ~~potential~~registration ~~benefits~~or ~~and~~qualification ~~expectations~~under ~~related to~~ the ~~terms~~securities ~~and~~laws ~~timing~~ of ~~the~~any such jurisdiction. The proposed Business Combination, ~~are~~will ~~forward-looking statements. Some of these forward-looking statements can~~ be ~~identified~~submitted byto the ~~use~~shareholders of forward-looking words, including “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” or other similar expressions. All forward-looking statements are based upon estimates and forecasts and reflect the ~~views, assumptions, expectations, and opinions of the~~ Company and ~~Veraxa,~~SPAC which are all subject to change due to various factors. Any such estimates, assumptions, expectations, forecasts, views or opinions, whether or not identified in this Communication, should be regarded as indicative, preliminary and for ~~illustrative~~their ~~purposes only and should not be relied upon as being necessarily indicative of future results~~consideration.

1PubCo filed a registration statement on Form F-4 (the “Registration Statement”) with the SEC on July 31, 2025, as amended from time to time, which was declared effective by the SEC on February 17, 2026. The Registration Statement includes preliminary and definitive proxy statements to be distributed to SPAC’s shareholders in connection with SPAC’s solicitation for proxies for the vote by SPAC’s shareholders in connection with the proposed Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to the Company’s shareholders in connection with the completion of the proposed Business Combination. SPAC and PubCo also will file other documents regarding the proposed Business Combination with the SEC.

~~The~~After ~~forward-looking~~the ~~statements~~Registration ~~and~~Statement was ~~financial~~declared ~~forecasts~~effective, ~~and~~SPAC ~~projections~~mailed ~~contained in this Communication are subject to~~ a ~~number~~definitive ofproxy ~~factors,~~statement ~~risks~~ and ~~uncertainties.~~other ~~Potential~~relevant ~~risks~~documents ~~and uncertainties that could cause the actual results~~ to ~~differ~~its ~~materially~~shareholders ~~from~~as those expressed or implied by forward-looking statements include, but are not limited to, changes in domestic and foreign business, market, financial, political and legal conditions; the timing and structure of the ~~Business~~record ~~Combination;~~date established ~~changes~~for tovoting on the proposed ~~structure of the~~ Business Combination. ~~that~~This ~~may~~Communication beis ~~required~~not ~~or appropriate as~~ a ~~result~~substitute offor ~~applicable laws or regulations;~~ the ~~inability~~Registration ofStatement, the definitive ~~parties~~proxy tostatement/prospectus ~~successfully~~ or ~~timely~~any ~~consummate the Business Combination and the~~ other ~~transactions~~document ~~in connection therewith, including as a result of any regulatory approvals~~ that ~~are~~SPAC ~~not~~has ~~obtained,~~sent ~~are delayed~~ or ~~are~~will ~~subject~~send to ~~unanticipated~~its ~~conditions~~shareholders ~~that~~in ~~could~~connection ~~adversely~~with ~~affect~~ the ~~combined company or the expected benefits of the~~ Business Combination. orSPAC’s ~~that the approval of the~~ shareholders ~~of the Company or Veraxa is not obtained; the risk that the business combination disrupts current plans~~ and ~~operations~~other ofinterested ~~the~~persons ~~Company~~are oradvised ~~Veraxa~~to asread, aonce ~~result~~available, of the ~~announcement~~preliminary ~~and~~proxy statement/prospectus ~~consummation of the Business Combination; the ability of Veraxa to grow~~ and ~~manage~~any ~~growth~~amendments ~~profitably~~thereto and, ~~retain~~once ~~its~~available, ~~key employees including its chief executive officer and executive team;~~ the ~~inability~~definitive toproxy ~~obtain~~statement/prospectus, orin ~~maintain~~connection the listing of Veraxa Biotech Holding AG’s (PubCo) securities on Nasdaq following the Business Combination; failure to realize the anticipated benefits of the Business Combination; risk relating to the uncertainty of the projected financial information with ~~respect to Veraxa; the amount of redemption requests made by the Company~~SPAC’s solicitation ~~shareholders and the amount~~ of ~~funds~~proxies ~~available in the Company trust account; the overall level of demand~~ for ~~Veraxa’s services; general economic conditions and other factors affecting Veraxa’s business; Veraxa’s ability to implement~~ its ~~business~~special ~~strategy;~~meeting ~~Veraxa’s ability to manage expenses; changes in applicable laws and governmental regulation and the impact~~ of ~~such~~shareholders ~~changes on Veraxa’s business, Veraxa’s exposure~~ to ~~litigation~~be ~~claims~~held ~~and other loss contingencies; the risks associated with negative press or reputational harm; Veraxa’s ability~~ to ~~protect patents~~approve, ~~trademarks~~among ~~and~~ other ~~intellectual property rights; any breaches of~~things, orthe ~~interruptions~~proposed intransactions, because ~~Veraxa’s~~these ~~technology~~documents ~~infrastructure;~~will ~~changes~~contain inimportant ~~tax~~information ~~laws~~about ~~and liabilities; and changes in legal~~SPAC, ~~regulatory~~PubCo, ~~political~~the ~~and~~Company ~~economic risks~~ and the ~~impact~~proposed ofBusiness ~~such changes on Veraxa’s business~~Combination. ~~The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors~~ Shareholders and ~~the~~investors ~~other~~may ~~risks~~also ~~and~~obtain ~~uncertainties~~a ~~described~~copy inof the ~~“Risk~~preliminary ~~Factors”~~or ~~section~~definitive ~~of PubCo’s Registration Statement (as defined below), the~~ proxy statement~~/consent~~, ~~solicitation~~once ~~statement/prospectus~~available, ~~discussed~~as ~~below~~well ~~and~~as other documents filed ~~by PubCo or the Company from time to time~~ with the ~~U.S.~~SEC ~~Securities~~regarding ~~and Exchange Commission (~~the ~~“SEC”).~~proposed ~~These~~transactions ~~filings identify~~ and ~~address~~ other ~~important~~documents ~~risks~~filed ~~and~~with ~~uncertainties that could cause actual events and results to differ materially from those contained in~~ the ~~forward-looking~~SEC ~~statements.~~by ~~In addition~~SPAC, ~~there~~without ~~may~~charge, beat ~~additional risks that neither~~ the ~~Company~~SEC’s ~~nor~~website located ~~Veraxa~~at ~~presently~~www.sec.gov ~~know,~~ or ~~that~~by ~~the~~directing ~~Company~~a orrequest ~~Veraxa currently believe are immaterial, that could also cause actual results~~ to ~~differ~~SPAC. ~~from~~The ~~those~~information contained ~~in the forward-looking statements. Forward-looking statements reflect the Company’s and Veraxa’s expectations~~on, ~~plans, projections~~ or ~~forecasts~~that ofmay ~~future~~be ~~events~~accessed ~~and~~through, ~~view. If any of~~ the ~~risks~~websites referenced ~~materialize~~in orthis ~~the~~document ~~Company’s~~is ornot ~~Veraxa’s~~incorporated ~~assumptions~~by ~~prove~~reference ~~incorrect~~into, ~~actual~~and ~~results~~is ~~could~~not ~~differ~~a ~~materially~~part ~~from~~of, ~~the~~this ~~results implied by these forward-looking statements~~document.

~~Forward-looking~~INVESTMENT ~~statements~~IN ~~speak~~ANY ~~only~~SECURITIES DESCRIBED asHEREIN ofHAS ~~the~~NOT ~~date~~BEEN ~~they~~APPROVED ~~are~~OR ~~made.~~DISAPPROVED ~~The~~BY ~~Company~~THE ~~and~~SEC ~~Veraxa~~OR ~~anticipate~~ANY ~~that~~OTHER ~~subsequent~~REGULATORY ~~events~~AUTHORITY ~~and~~NOR ~~developments~~HAS ~~may~~ANY ~~cause~~AUTHORITY ~~their~~PASSED ~~assessments~~UPON toOR ENDORSED ~~change.~~THE ~~However,~~MERITS ~~while~~OF ~~PubCo,~~THE ~~the~~OFFERING ~~Company~~OR ~~and~~THE ~~Veraxa~~ACCURACY ~~may~~OR ~~elect~~ADEQUACY toOF ~~update~~THE ~~these~~INFORMATION ~~forward-looking~~CONTAINED ~~statements at some point in the future, PubCo, the Company and Veraxa specifically disclaim any obligation to do so, except as required by law~~HEREIN. ~~The~~ANY ~~inclusion~~REPRESENTATION ofTO ~~any~~THE ~~statement~~CONTRARY IS inA ~~this~~CRIMINAL ~~document does not constitute an admission by Veraxa nor the Company or any other person that the events or circumstances described in such statement are material~~OFFENSE. These forward-looking statements should not be relied upon as representing the Company’s or Veraxa’s assessments as of any date subsequent to the date of this document. Accordingly, undue reliance should not be placed upon the forward-looking statements. In addition, the analyses of Veraxa and the Company contained herein are not, and do not purport to be, appraisals of the securities, assets or business of Veraxa, the Company or any other entity.

~~Important Information About the Proposed Transactions and Where to Find It~~2

~~This~~Participants Communication relates to a proposed Business Combination between Veraxa and the Company. This document does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in ~~any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under~~ the ~~securities laws of any such jurisdiction. The proposed Business Combination will be submitted to the shareholders of Veraxa and the Company for their consideration.~~Solicitation

2SPAC, PubCo and the Company and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from SPAC’s shareholders in connection with the proposed transactions. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of SPAC’s shareholders in connection with the proposed transactions will be set forth in PubCo’s proxy statement/prospectus when it is filed with the SEC. You can find more information about SPAC’s directors and executive officers in SPAC’s final prospectus filed with the SEC on August 12, 2024. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.

~~PubCo intends~~No toOffer ~~file~~or a registration statement on Form F-4 (the “Registration Statement”) with the SEC which will include preliminary and definitive proxy statements to be distributed to the Company’s shareholders in connection with the Company’s solicitation for proxies for the vote by the Company’s shareholders in connection with the proposed Business Combination and other matters as described in the Registration Statement, as well as the prospectus relating to the offer of the securities to be issued to Veraxa’s shareholders in connection with the completion of the proposed Business Combination. the Company and PubCo also will file other documents regarding the proposed Business Combination with the SEC.Solicitation

~~After~~This ~~the~~Communication ~~Registration~~is ~~Statement~~for informational ~~has~~purposes ~~been~~only ~~filed~~ and ~~declared~~shall ~~effective,~~not ~~the~~constitute ~~Company~~an ~~will~~offer ~~mail~~to asell ~~definitive~~or ~~proxy~~the ~~statement~~solicitation ~~and~~of ~~other~~an ~~relevant~~offer ~~documents~~ to ~~its~~buy ~~shareholders~~any assecurities ofpursuant to the ~~record date established for voting on the~~ proposed Business Combination. ~~This~~or ~~Communication is not a substitute for the Registration Statement~~otherwise, ~~the~~nor ~~definitive~~shall ~~proxy~~there ~~statement/prospectus~~be or any ~~other~~sale ~~document~~of ~~that~~securities ~~the Company will send to its shareholders~~ in ~~connection with the Business Combination. The Company’s shareholders and other interested persons are advised to read, once available, the preliminary proxy statement/prospectus and~~ any ~~amendments~~jurisdiction ~~thereto~~in ~~and,~~which ~~once available,~~ the ~~definitive proxy statement/prospectus~~offer, ~~in connection with the Company’s~~ solicitation or ofsale ~~proxies~~would ~~for~~be ~~its~~unlawful ~~special~~prior ~~meeting of shareholders~~ to ~~be held to approve, among other things,~~ the ~~proposed~~registration ~~transactions,~~or ~~because~~qualification ~~these~~under ~~documents will contain important information about~~ the ~~Company,~~securities ~~PubCo,~~laws ~~Veraxa~~of ~~and~~any ~~the~~such ~~proposed Business Combination~~jurisdiction. ~~Shareholders~~No ~~and~~offer ~~investors may also obtain a copy~~ of ~~the~~securities shall ~~preliminary~~be ormade ~~definitive~~except ~~proxy statement, once available, as well as other documents filed with the SEC regarding the proposed transactions and other documents filed with the SEC~~ by ~~the~~means ~~Company,~~of ~~without charge, at the SEC’s website located at www.sec.gov or by directing~~ a ~~request~~prospectus tomeeting the ~~Company.~~requirements ~~The~~of ~~information~~Section ~~contained~~10 ~~on,~~of ~~or that may be accessed through,~~ the ~~websites~~Securities ~~referenced in this document is not incorporated by reference into, and is not a part of, this document~~Act.

~~INVESTMENT~~Item IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN9.01 ~~ANY~~Financial ~~REPRESENTATION~~Statements TOand ~~THE CONTRARY IS A CRIMINAL OFFENSE~~Exhibits.

~~Participants~~The following inexhibits ~~the~~are ~~Solicitation~~being filed herewith:

~~The~~(d) Company, PubCo and Veraxa and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitations of proxies from the Company’s shareholders in connection with the proposed transactions. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of the Company’s shareholders in connection with the proposed transactions will be set forth in PubCo’s proxy statement/prospectus when it is filed with the SEC. You can find more information about the Company’s directors and executive officers in the Company’s final prospectus filed with the SEC on August 12, 2024. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests will be included in the proxy statement/prospectus when it becomes available. Shareholders, potential investors and other interested persons should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from the sources indicated above.Exhibits

No Offer or Solicitation

Exhibit Number		Description
99.1		Press Release, dated March 2, 2026.

This Communication is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities pursuant to the proposed Business Combination or otherwise, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.3

3SIGNATURES

~~Item~~Pursuant ~~9.01~~to ~~Financial~~the ~~Statements~~requirements ~~and~~of ~~Exhibits~~the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(d) Exhibits

Dated: February 27, 2026	VOYAGER ACQUISITION CORP.

	By:	/s/ Adeel Rouf
	Name:	Adeel Rouf
	Title:	President and Chief Executive Officer

~~The following exhibits are being filed herewith:~~4

Exhibit Number		Description
2.1		Second Amendment and Waiver to Business Combination Agreement, dated as of February 2, 2026, by and among Voyager Acquisition Corp., Veraxa Biotech AG, and Oliver Baumann.
3.1		Form of Second Amended and Restated Memorandum and Articles of Association of Voyager Acquisition Corp.
10.1		First Amendment to Sponsor Support Agreement, dated as of February 2, 2026, by and among VERAXA Biotech AG, Voyager Acquisition Corp., and Voyager Acquisition Sponsor Holdco LLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 3, 2026	VOYAGER ACQUISITION CORP.
	By:	/s/ Adeel Rouf
	Name:	Adeel Rouf
	Title:	President and Chief Executive Officer

Filing Compare · Voyager Acquisition Corp./Cayman Islands